Clinical study of efficacy of hydroxyapatite.
The cleaved part of collagen during collagen formation was secreted into the circulation. The present study used this remnant part of collagen called procollagen type 1 propeptide at carboxyl terminal (PICP) as a bone formation marker Clinical study of efficacy of hydroxyapatite tablet (800 mg) in 47 menopausal women with bone resorption marker, (CTx) below 0.330 ng/ml. and their general condition is healthy. All cases were free of medication at least one month before the present study. After one month, the mean of PICP was 1452.28 ng/ml SD = 625.58 which is significantly higher than the mean of baseline control, 930.98 ng/ml SD=477.44 (p=0.0001).
Srimongkol
Thaiyin
T
PrapinKloa Hospital.
Bunyaratavej
Narong
N
D001672:Biocompatible Materials / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers; D001862:Bone Resorption; D001842:Bone and Bones / Q000187:drug effects*; D024042:Collagen Type I / Q000032:analysis*; D017886:Durapatite / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D016896:Treatment Outcome
D001672:Biocompatible Materials; D015415:Biomarkers; D024042:Collagen Type I; D017886:Durapatite